Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma

[1]  W. Pomat,et al.  Trachoma, Anti-Pgp3 Serology, and Ocular Chlamydia trachomatis Infection in Papua New Guinea , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  M. White,et al.  The utility of serology for elimination surveillance of trachoma , 2018, Nature Communications.

[3]  M. Burton,et al.  Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with Chlamydia trachomatis , 2018, Wellcome open research.

[4]  R. Wiegand,et al.  Comparison of Platforms for Testing Antibody Responses against the Chlamydia trachomatis Antigen Pgp3 , 2017, The American journal of tropical medicine and hygiene.

[5]  C. Roberts,et al.  Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati , 2017, PLoS neglected tropical diseases.

[6]  C. Roberts,et al.  Active Trachoma Cases in the Solomon Islands Have Varied Polymicrobial Community Structures but Do Not Associate with Individual Non-Chlamydial Pathogens of the Eye , 2017, bioRxiv.

[7]  J. Kool,et al.  Integrated Mapping of Yaws and Trachoma in the Five Northern-Most Provinces of Vanuatu , 2017, PLoS neglected tropical diseases.

[8]  D. Mabey,et al.  Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies , 2017, PLoS neglected tropical diseases.

[9]  A. Solomon,et al.  Mapping Trachoma in the Solomon Islands: Results of Three Baseline Population-Based Prevalence Surveys Conducted with the Global Trachoma Mapping Project , 2016, Ophthalmic epidemiology.

[10]  Anthea M Burnett,et al.  Population-Based Trachoma Mapping in Six Evaluation Units of Papua New Guinea , 2016, Ophthalmic epidemiology.

[11]  D. Mabey,et al.  Community seroprevalence survey for yaws and trachoma in the Western Division of Fiji , 2016, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[12]  M. Burton,et al.  The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment , 2016, PLoS neglected tropical diseases.

[13]  H. Tutill,et al.  Low Prevalence of Conjunctival Infection with Chlamydia trachomatis in a Treatment-Naïve Trachoma-Endemic Region of the Solomon Islands , 2016, PLoS neglected tropical diseases.

[14]  M. Burton,et al.  Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease , 2016, PLoS neglected tropical diseases.

[15]  D. Mabey,et al.  Low Prevalence of Ocular Chlamydia trachomatis Infection and Active Trachoma in the Western Division of Fiji , 2016, PLoS neglected tropical diseases.

[16]  M. Gambhir,et al.  Serological Measures of Trachoma Transmission Intensity , 2015, Scientific Reports.

[17]  S. Brooker,et al.  The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study , 2015, Ophthalmic epidemiology.

[18]  C. Drakeley,et al.  Sample size determination for estimating antibody seroconversion rate under stable malaria transmission intensity , 2015, Malaria Journal.

[19]  D. Mabey,et al.  Prevalence of sexually transmitted infections in female clinic attendees in Honiara, Solomon Islands , 2015, BMJ Open.

[20]  H. Weiss,et al.  Risk Factors for Active Trachoma and Ocular Chlamydia trachomatis Infection in Treatment-Naïve Trachoma-Hyperendemic Communities of the Bijagós Archipelago, Guinea Bissau , 2014, PLoS neglected tropical diseases.

[21]  Gretchen A. Stevens,et al.  Causes of vision loss worldwide, 1990-2010: a systematic analysis. , 2013, The Lancet. Global health.

[22]  S. West,et al.  Association between Ocular Bacterial Carriage and Follicular Trachoma Following Mass Azithromycin Distribution in The Gambia , 2013, PLoS neglected tropical diseases.

[23]  Elizabeth McCarthy,et al.  Development and Evaluation of a Next-Generation Digital PCR Diagnostic Assay for Ocular Chlamydia trachomatis Infections , 2013, Journal of Clinical Microbiology.

[24]  B. Munoz,et al.  CT694 and pgp3 as Serological Tools for Monitoring Trachoma Programs , 2012, PLoS neglected tropical diseases.

[25]  H. Weiss,et al.  What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting. , 2011, Investigative ophthalmology & visual science.

[26]  B. Munoz,et al.  Constant ocular infection with Chlamydia trachomatis predicts risk of scarring in children in Tanzania. , 2009, Ophthalmology.

[27]  H. Taylor.  Trachoma: A Blinding Scourge from the Bronze Age to the Twenty-first Century , 2008 .

[28]  Jonathan Scott Friedlaender,et al.  The Genetic Structure of Pacific Islanders , 2008, PLoS genetics.

[29]  D. Mabey,et al.  Operational evaluation of the use of photographs for grading active trachoma. , 2006, The American journal of tropical medicine and hygiene.

[30]  D. Zenner,et al.  Sexually transmitted diseases and HIV/AIDS in Vanuatu: a cause for concern and action. , 2005, The New Zealand medical journal.

[31]  R. Peeling,et al.  Strategies for control of trachoma: observational study with quantitative PCR , 2003, The Lancet.

[32]  T. Lietman,et al.  Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? , 2003, The Journal of infectious diseases.

[33]  B. Munoz,et al.  Progression of active trachoma to scarring in a cohort of Tanzanian children , 2001, Ophthalmic epidemiology.

[34]  C. Gilbert,et al.  International agency for the prevention of blindness. , 1979, The British journal of ophthalmology.

[35]  Rosanna W. Peeling,et al.  Neglected Tropical Diseases : Rationale and Target Product Profiles , 2018 .

[36]  S. West,et al.  A simple system for the assessment of trachoma and its complications. , 1987, Bulletin of the World Health Organization.